Key result
Class III antidysrhythmic drugs have electrophysiological properties that may limit their clinical utility, while endogenous adenosine offers a novel therapeutic approach for dysrhythmias.
This review highlights the limitations of 'pure' class III antidysrhythmic agents and introduces endogenous adenosine as a novel therapeutic approach.
Answers are grounded in this paper and cite their sources.
May warrant caution with class III agents; leaves open adenosine modulation as a novel dysrhythmia target for prospective trials.
Antidysrhythmic drug research has recently focused on developing agents whose primary electrophysiological action is to selectively prolong repolarization. The major impetus for the development of these ‘pure’ class III agents was the assumption that their smaller effects on conduction velocity and contractility would make them safer drugs than class I agents. In this article, we will review some recently discovered electrophysiological properties of class III drugs that may markedly limit their clinical utility. Lastly, a novel therapeutic approach that exploits the antidysrhythmic properties of endogenous adenosine is described.
No takes yet. Share an insight, caveat, or question.
Dennis et al. (1996) conducted a review in Dysrhythmias. Class III antidysrhythmic drugs and endogenous adenosine was evaluated. Class III antidysrhythmic drugs have electrophysiological properties that may limit their clinical utility, while endogenous adenosine offers a novel therapeutic approach for dysrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: